Plain English summary not yet available
The full original text is available below. Check back soon as we process this bill.
IV
116TH CONGRESS
1ST SESSION
H. RES. 584
Expressing support for the designation of September 2019 as ‘‘National
Prostate Cancer Awareness Month’’.
IN THE HOUSE OF REPRESENTATIVES
SEPTEMBER 24, 2019
Mr. PAYNE (for himself, Mr. MULLIN, and Mr. MEEKS) submitted the fol-
lowing resolution; which was referred to the Committee on Energy and
Commerce, and in addition to the Committee on Ways and Means, for
a period to be subsequently determined by the Speaker, in each case for
consideration of such provisions as fall within the jurisdiction of the com-
mittee concerned
RESOLUTION
Expressing support for the designation of September 2019
as ‘‘National Prostate Cancer Awareness Month’’.
Whereas an estimated 3,110,403 men in the United States
live with prostate cancer;
Whereas, according to the National Cancer Institute, the per-
centage of newly diagnosed prostate cancer cases in men
under 65 has significantly increased and stands at 41.9
percent;
Whereas 1 in 9 men in the United States will be diagnosed
with prostate cancer in their lifetimes;
VerDate Sep 11 2014
01:42 Sep 25, 2019
Jkt 089200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6300
E:\BILLS\HR584.IH
HR584
pamtmann on DSKBC07HB2PROD with BILLS
2
•HRES 584 IH
Whereas prostate cancer is the most commonly diagnosed
nonskin cancer and the second-leading cause of cancer-
related deaths among men in the United States;
Whereas the American Cancer Society estimates that in
2019, 174,650 men will be diagnosed with, and more
than 31,620 men will die of, prostate cancer;
Whereas the odds of developing prostate cancer rise rapidly
after age 50;
Whereas African-American men suffer from a prostate cancer
incidence rate that is significantly higher than that of
White men and have more than double the prostate can-
cer mortality rate than that of White men;
Whereas some veterans are at an increased risk of prostate
cancer due to chemical or radiation exposure during mili-
tary service;
Whereas a study conducted at the Portland VA Medical Cen-
ter and Oregon Health and Science University found that
veterans exposed to Agent Orange were at an increased
risk for both developing prostate cancer and developing
more aggressive forms of the disease;
Whereas having a father or brother with prostate cancer
more than doubles the risk of a man developing prostate
cancer, with a higher risk for men who have a brother
with the disease and the highest risk for men with several
affected relatives;
Whereas screening by a digital rectal examination and a pros-
tate-specific antigen blood test can detect the disease at
the earlier, more treatable stages, which could increase
the chances of survival for more than 5 years to nearly
100 percent;
VerDate Sep 11 2014
01:42 Sep 25, 2019
Jkt 089200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6300
E:\BILLS\HR584.IH
HR584
pamtmann on DSKBC07HB2PROD with BILLS
3
•HRES 584 IH
Whereas prostate cancer is almost always diagnosed with a
needle biopsy where the prostate is mapped and tissue
cores removed from at least a dozen sites;
Whereas even with state-of-the-art laboratory techniques and
specimen tracking, the peer-reviewed literature reports
that as many as 2.5 percent of prostate biopsy patients
are affected by biopsy tissue switching or contamination
leading to misdiagnosis;
Whereas misdiagnosis can result in inappropriate over- or
under-treatment of men;
Whereas only 30 percent of men survive more than 5 years
if diagnosed with prostate cancer after the cancer has
metastasized;
Whereas there are no noticeable symptoms of prostate cancer
in the early stages, making appropriate screening critical;
Whereas ongoing research promises further improvements in
prostate cancer prevention, early detection, and treat-
ment; and
Whereas educating people in the United States, including
health care providers, about prostate cancer and early de-
tection strategies is crucial to saving the lives of men and
preserving and protecting families: Now, therefore, be it
Resolved, That the House of Representatives—
1
(1) expresses support for the designation of
2
‘‘National Prostate Cancer Awareness Month’’;
3
(2) declares that steps should be taken—
4
(A) to raise awareness about the impor-
5
tance of screening methods for, and treatment
6
of, prostate cancer;
7
VerDate Sep 11 2014
01:42 Sep 25, 2019
Jkt 089200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\HR584.IH
HR584
pamtmann on DSKBC07HB2PROD with BILLS
4
•HRES 584 IH
(B) to encourage research—
1
(i) to improve screening and treat-
2
ment for prostate cancer;
3
(ii) to discover the causes of prostate
4
cancer; and
5
(iii) to develop a cure for prostate
6
cancer;
7
(C) support Medicare payment policies
8
that will improve diagnostic accuracy and elimi-
9
nate prostate cancer misdiagnosis due to biopsy
10
contamination or specimen switching; and
11
(D) to continue to consider ways for im-
12
proving access to, and eliminating racial dis-
13
parities in, the quality of health care services
14
for detecting and treating prostate cancer; and
15
(3) calls on the people of the United States, in-
16
terest groups, and affected persons—
17
(A) to promote awareness of prostate can-
18
cer;
19
(B) to take an active role in the fight to
20
end the devastating effects of prostate cancer
21
on individuals, families, and the economy; and
22
VerDate Sep 11 2014
01:42 Sep 25, 2019
Jkt 089200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\HR584.IH
HR584
pamtmann on DSKBC07HB2PROD with BILLS
5
•HRES 584 IH
(C) to observe National Prostate Cancer
1
Awareness Month with appropriate ceremonies
2
and activities.
3
Æ
VerDate Sep 11 2014
01:42 Sep 25, 2019
Jkt 089200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6301
E:\BILLS\HR584.IH
HR584
pamtmann on DSKBC07HB2PROD with BILLS